Comparing SG&A Expenses: Alkermes plc vs Travere Therapeutics, Inc. Trends and Insights

A Decade of SG&A Trends: Alkermes plc vs Travere Therapeutics, Inc.

In the ever-evolving pharmaceutical landscape, understanding the financial strategies of key players is crucial. Over the past decade, Alkermes plc and Travere Therapeutics, Inc. have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Alkermes plc's SG&A expenses surged by approximately 245%, reflecting a strategic expansion and investment in operational capabilities. In contrast, Travere Therapeutics, Inc. experienced a remarkable 345% increase, indicating aggressive growth and market penetration efforts.

By 2023, Alkermes plc's SG&A expenses reached nearly 690 million, while Travere's expenses climbed to around 266 million. This divergence highlights differing business models and market strategies. As the pharmaceutical industry continues to innovate, these financial insights provide a window into the competitive dynamics and strategic priorities of these two companies.